- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17:46 | Roche stops work on experimental SMA drug | ||
| 16:46 | Novartis pays $2B to land a startup's breast cancer drug | ||
| 14:46 | Rhythm obesity drug wins broader use from FDA | ||
| Do | Novo uses FDA voucher to win speedy approval of higher-dose Wegovy | ||
| Do | Lilly's three-pronged obesity drug hits goal in large diabetes trial | ||
| Do | Pfizer aims for wider use of PARP drug in prostate cancer with new data | ||
| Do | A biotech VC sees early signs of a turnaround for startups | ||
| Do | AstraZeneca to boost cell therapy capabilities with new China investment | ||
| Mi | RBC: Revolution, Xenon, Arrowhead among top takeover targets | ||
| Mi | J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections | ||
| Mi | Aspen's fresh Parkinson's data; Aldeyra tanks following FDA rejection | ||
| Mi | Crossbow raises $77M for new cancer immunotherapies | ||
| Mi | Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers | ||
| Di | Bicycle to lay off 30% of staff, pivot away from Padcev challenger | ||
| Di | Pfizer's Ibrance successor moves forward with new study data | ||
| Di | Federal court blocks RFK Jr.'s moves to upend US vaccine policy | ||
| Di | R1 starts up with $78M, aiming for a better kidney drug | ||
| Mo | CytomX surges on positive data for 'masked' ADC in colorectal cancer | ||
| Mo | Structure's GLP-1 pill shows 'best-in-class' potential in obesity trial | ||
| Mo | Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy | ||
| 13.03. | With FDA go ahead, a China biotech notches a first in cell therapy testing | ||
| 13.03. | GSK's RSV vaccine wins broader FDA clearance | ||
| 13.03. | Evotec, Vistagen lay off staff; Immutep shares collapse on study failure | ||
| 13.03. | New FDA guidance could elevate pharma's biosimilar market | ||
| 12.03. | Lilly warns GLP-1 knockoffs may be 'dangerous,' escalating war with compounders |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.